Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VINS Polyvalent Antivenom
- Development stage
- Phase 2
- Lead developer
- VINS Bio Products
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VINS Polyvalent Antivenom (VPAV) is a purified, equine-derived polyvalent antivenom produced by VINS Bio Products Ltd. in India. It is specifically designed to treat snakebite envenoming caused by the "Big Four" venomous snakes of the Indian subcontinent: the Indian cobra (*Naja naja*), the Common krait (*Bungarus caeruleus*), the Russell's viper (*Daboia russelii*), and the Saw-scaled viper (*Echis carinatus*). The antivenom works by binding to and neutralizing various venom components, including phospholipases A2 (PLA2), three-finger toxins (3FTx), snake venom metalloproteinases (SVMP), and serine proteases. While effective against the Big Four in India, its efficacy varies geographically against related species and subspecies in neighboring regions like Bangladesh, Pakistan, and Sri Lanka due to venom variation. It is administered intravenously and is associated with a risk of acute antivenom-related anaphylaxis (ARA).
- Brand names
- VINS Polyvalent Antivenom
- Other names
- Indian VINS Polyvalent AntivenomVins Polyvalent AntivenomVins Antivenom
02
Targets
svPLA2 (Snake venom phospholipase A2)SVMP (Snake venom metalloproteinase)3FTx (Three-finger toxin)PLA2 (Phospholipase A2 group IID)SVSP (Snake venom serine protease)
Beyond the preview
Go deeper on VINS Polyvalent Antivenom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VINS Polyvalent Antivenom.